Summary
Background
Helicobacter pylori is one of the most common bacterial infections, seen in humans worldwide and its possible relationship to different diseases is a focus of attention nowadays. The aim of this study was to analyse the effects ofH. Pylori eradication on proteinuria.
Methods
Ninety-nine patients suffering from dyspeptic complaints were recruited in this prospective study. The patients were divided into two groups according to the presence ofH. pylori infection. Thus, a total of 67 H. pylori positive and 32 H. pylori negative patients were studied. TheH. pylori positive patients’ group was divided into two groups according to response toH. pylori eradication treatment. A total of three groups were formed, viz; group 1 comprises of patients who areH. pylori positive and responds positively toH. pylori eradication therapy, group 2 comprises of patients who areH. pylori positive and responds negatively toH. pylori eradication therapy and group 3 is the control group and comprises of patients that areH. pylori negative. Urine samples to obtain the protein/creatinine ratio were collected initially and at the end of the study from all patients.
Results
Mean difference levels (pre- and post-treatment difference) of urine protein/creatinine ratio was 0.055 ± 0.13 in group 1. The ratio was − 0.0007 ± 0.0067 in group 2 and − 0.0022 ± 0.008 in group 3. A statistically significant difference was found in group 1 compared to the other groups in terms of mean difference levels of protein/creatinine ratios (p < 0.001).
Conclusion
As a result of our study, treatment ofH. pylori eradication significantly reduced the proteinuria within the normal limits.
Zusammenfassung
Hintergrund
Helicobacter pylori ist weltweit eine der häufigsten bakteriellen Infektionen beim Menschen. Immer mehr Aufmerksamkeit wird heutzutage einem möglichen Zusammenhang mit verschiedenen anderen Erkrankungen gewidmet. Ziel der vorliegenden Studie war es, die Wirkung einer HP Eradikation auf die Proteinurie zu analysieren.
Methodik
99 Patienten mit dyspeptischen Beschwerden wurden für diese Studie rekrutiert. Die Patienten wurden in 2 Gruppen je nach Nachweis eines HP geteilt. So wurden 67 HP positive und 32 HP negative Patienten untersucht. Die HP positiven Patienten wurden entsprechend dem Ansprechen auf die Eradikationstherapie unterteilt. Insgesamt wurden somit 3 Gruppen gebildet: Gruppe 1: HP positive Patienten, die auf die Therapie ansprachen; Gruppe 2: HP positive Patienten, die nicht ansprachen, und Gruppe 3: HP negative Patienten (die als Kontrolle dienten). Harnproben zur Analyse des Protein/Kreatinin Quotienten (P/K Qu) wurden initial und am Ende der Studie von allen Patienten gesammelt.
Ergebnisse
Die P/K Qu Werte der mittleren Differenz vor und nach Therapie lagen bei 0.055 ± 0.13 in Gruppe 1. Der Quotient war bei − 0.0007 ± 0.0067 in Gruppe 2 und bei − 0.0022 ± 0.008 in Gruppe 3. Ein statistisch signifikanter Unterschied wurde bezüglich der mittleren Differenzen der P/K Qu in Gruppe 1 im Vergleich zu den anderen Gruppen gefunden (p < 0,001).
Schlussfolgerung
Eine erfolgreiche Eradikation von HP reduziert die Eiweißausscheidung innerhalb des Normalbereichs signifikant.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Kanbay M, Kanbay A, Boyacioglu S. Helicobacter pylori infection as a possible risk factor for respiratory system disease: a review of the literature. Respir Med. 2007;101(2):203–9.
Oshima T, Ozono R, Yano Y, Oishi Y, Teragawa H, Higashi Y, et al. Association of Helicobacter pylori infection with systemic inflammation and endothelial dysfunction in healthy male subjects. J Am Coll Cardiol. 2005;45(8):1219–22.
Franceschi F, Gasbarrini A. Helicobacter pylori and extra-gastric diseases. Best Pract Res Clin Gastroenterol. 2007;21(2):325–34.
Bodger K, Crabtree JE. Helicobacter pylori and gastric inflammation. Br Med Bull. 1998;54(1):139–50.
Konturek SJ, Konturek PC, Pieniazek P, Bielański W. Role of Helicobacter pylori infection in extragastroduodenal disorders: introductory remarks. J Physiol Pharmacol. 1999;50(5):683–94.
Bohr UR, Annibale B, Franceschi F, Roccarina D, Gasbarrini A. Extragastric manifestations of Helicobacter pylori infection—other Helicobacters. Helicobacter. 2007;12(Suppl 1):45–53.
Kanbay M, Kasapoglu B, Akcay A. An occult risk factor for proteinuria: Helicobacter pylori infection. Med Hypotheses. 2007;69(3):709–10.
Nagashima R, Maeda K, Yuda F, Kudo K, Saitoh M, Takahashi T. Helicobacter pylori antigen in the glomeruli of patients with membranous nephropathy. Virchows Arch. 1997;431(4):235–9.
Moriyama T, Kaneko T, Fujii M, Tsubakihara Y, Kawano S, Imai E. High prevalence of Helicobacter pylori infection in Japanese patients with membranous nephropathy. Aliment Pharmacol Ther. 2006;2(1):189–93
Sugimoto T, Furukawa T, Maeda T, Somura M, Uzu T, Kashiwagi A. Marked reduction of proteinuria after eradication of gastric Helicobacter pylori infection in a patient with membranous nephropathy: coincidental or associated? Intern Med. 2007;46(17):1483–4.
Hirschl AM. Helicobacter pylori: pathogens, pathomechanisms and epidemiology. Wien Klin Wochenschr. 1994;106(17):538–42.
Kanbay M, Kasapoglu B, Turgut F, Uz E, Bavbek N, Akcay A. Helicobacter pylori: a major risk factor for endothelial dysfunction? Med Hypotheses. 2007;69(1):227–8.
Conflict of interest
The authors declare that there is no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Aydogan, T., Ulas, T., Selcoki, Y. et al. Effects ofHelicobacter pylori eradication on proteinuria: a prospective study. Wien Klin Wochenschr 124, 241–244 (2012). https://doi.org/10.1007/s00508-012-0150-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00508-012-0150-0